Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
Holding GB:AZN?
Track your performance easily
AZN Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range9,461.00p - 13,388.00p
Previous Close9,922p
Volume216.69K
Average Volume (3M)2.08M
Market Cap
£150.88B
Enterprise Value171.42B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)30.1
Beta0.92
Next Earnings
Nov 12, 2024EPS Estimate
£1.58Last Dividend Ex-Date
Aug 08, 2024Dividend Yield2.31%
Share Statistics
EPS (TTM)3.29
Shares Outstanding1,550,294,658
10 Day Avg. Volume2,942,258
30 Day Avg. Volume2,082,559
Standard Deviation0.06
R-Squared0.10
Alpha0.00878
Financial Highlights & Ratios
Price to Book (P/B)389.25
Price to Sales (P/S)4.27
Price to Cash Flow (P/CF)18.90
P/FCF Ratio26.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit4.57
Enterprise Value/Ebitda18.87
Forecast
1Y Price Target
13,689.45pPrice Target Upside40.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
AstraZeneca News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAstraZeneca is expecting a very intense clinical newsflow in 2025 and is reporting only meaningful readouts that are able each to result in blockbuster opportunities.
Oncology PipelineAstraZeneca's innovations in cancer treatment are seen as a major advantage.
Regulatory UpdatesAnalysts expect focus to remain on datopotamab TL01 approval, which presents a positive risk-reward scenario.
Bears Say
Clinical Trial ResultsThe OS data in the non-squamous, non-AGA population (majority of non-squamous) is weak, with only 1.3m improvement in OS, and HR=0.89.
Product SafetyThere are concerns about the toxicity of Volrustomig, with a high percentage of Grade 3/4 treatment-related adverse events and discontinuations.
Regulatory ApprovalThere is suspicion about a straight approval of Dato-Dxd by the FDA over the coming weeks, with a delayed answer looking like a reasonable assumption.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
14.70% Mutual Funds
0.02% Other Institutional Investors
76.66% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9461.00p and its highest was 13388.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Nov 12, 2024 which is in 5 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Jul 25, 2024. The company reported 1.528p earnings per share for the quarter, beating the consensus estimate of 1.517p by 0.012p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 77.6p which represents an annual dividend yield of 2.31%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is £1.58.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,303,800 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.528p in its last earnings report, beating expectations of 1.517p. Following the earnings report the stock price went down -1.261%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
13,689.45p (40.69% Upside)
13,689.45p (40.69% Upside)
Insider Transactions
Bought Shares
Worth £235.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.32%
12-Months-Change
Fundamentals
Return on Equity
16.83%
Trailing 12-Months
Asset Growth
8.70%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZN Stock 12 Month Forecast
Average Price Target
13,689.45p
▲(40.69% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
24/29 ratings generated profit
1 Year Average Return
+13.87%
reiterated a sell rating 2 days ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 82.76% of your transactions generating a profit, with an average return of +13.87% per trade.
---